Investor Relations - MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.

SEC Filings

Form	Description	Filing date	View
8-K	Report of unscheduled material events or corporate event	Mar 31, 2026	View HTML 0001193125-26-133346.pdf 0001193125-26-133346.rtf 0001193125-26-133346.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-K	Annual report which provides a comprehensive overview of the company for the past year	Mar 31, 2026	View HTML 0001193125-26-134813.pdf 0001193125-26-134813.rtf 0001193125-26-134813.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K	Report of unscheduled material events or corporate event	Mar 27, 2026	View HTML 0001193125-26-127931.pdf 0001193125-26-127931.rtf 0001193125-26-127931.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
3	Initial filing by director officer or owner of more than ten percent	Mar 23, 2026	View HTML 0001193125-26-119823.pdf 0001193125-26-119823.rtf 0001193125-26-119823.xls

Data provided by Kaleidoscope.